25 percent of lung cancer patients are candidates for surgery. AcuityBio’s drug-eluting polymer implant, ABC103, would be administered during initial tumor removal surgery and prevent recurrence.
ABC103: Demonstrated Efficacy Combines Approved Products
Safety and Efficacy in preclinical models
Excellent long-term (>60day) safety in rodent and large animal resection models (rabbit and pig)
Long-term targeted delivery of therapeutic levels of paclitaxel to areas at highest risk for harboring residual cancer cells
Compatibility with existing standard of care procedures approved devices using approved and efficacious drug preventing recurrence
Approved for use to treat many cancers including lung cancer
Biodegradable Polymers for Coating
Used in multiple FDA approved products
Staple line buttress
ABC Technology can be used to deliver many compounds.
Our product candidate is based on technology developed and patented by AcuityBio; which can deliver many drugs and be applied to additional indications besides lung cancer.
Our technology can be applied to many delivery challenges please inquire about co-development opportunities